June 1, 2024Journal of Clinical Oncology

Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).

View Full Paper

Ask AI

Bookmark

High pathologic complete response rates occurred following neoadjuvant pembrolizumab in patients with locally advanced resectable cutaneous squamous cell carcinoma.
A pathologic complete response rate of 57% was documented among evaluable patients, and postoperative radiotherapy was successfully de-escalated in 54% overall.
Phase II single-arm neoadjuvant trial evaluated multiplex immunofluorescence biomarkers in the tumor microenvironment, supporting treatment de-escalation strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates high pathologic complete response rates in locally advanced cutaneous squamous cell carcinoma, highlighting potential for radiotherapy de-escalation.

Cite This Study

Amatore et al. (2024) studied this question.

synapsesocial.com/papers/68e66b13b6db6435875f63ce https://doi.org/10.1200/jco.2024.42.16_suppl.9591

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates high pathologic complete response rates in locally advanced cutaneous squamous cell carcinoma, highlighting potential for radiotherapy de-escalation.

Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).

Key Points

Discussion

Implication

Cite This Study

Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider